Clinical Trial Update: Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 clinical trial evaluating growth hormone and/or rosiglitazone for HIV-associated lipodystrophy syndrome with insulin resistance; completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hiv-associated Lipodystrophy Syndrome
• Insulin Resistance
• Metabolic Syndrome

Drugs mentioned

• Growth Hormone (somatropin)
• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: HIV-Associated Lipodystrophy Syndrome, Insulin Resistance | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-02-13